Valeant Pharmaceuticals Intl Inc (VRX) Director Purchases C$278,000.00 in Stock

Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De bought 20,000 shares of the business’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average cost of C$13.90 per share, for a total transaction of C$278,000.00.

Schutter Richard Urbain De also recently made the following trade(s):

  • On Wednesday, March 15th, Schutter Richard Urbain De bought 10,000 shares of Valeant Pharmaceuticals Intl stock. The shares were acquired at an average cost of C$10.80 per share, for a total transaction of C$108,000.00.

Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) traded down 0.82% on Friday, hitting $18.21. 749,558 shares of the stock were exchanged. The stock’s market cap is $6.34 billion. The company’s 50 day moving average is $14.19 and its 200-day moving average is $18.44. Valeant Pharmaceuticals Intl Inc has a 52-week low of $11.20 and a 52-week high of $42.25.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Director Purchases C$278,000.00 in Stock” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/05/19/valeant-pharmaceuticals-intl-inc-vrx-director-purchases-c278000-00-in-stock.html.

A number of research firms have commented on VRX. Royal Bank of Canada reissued a “sector perform” rating and set a C$29.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, February 28th. Scotiabank cut their target price on shares of Valeant Pharmaceuticals Intl from C$17.00 to C$15.00 and set a “sector perform” rating on the stock in a research report on Friday, February 17th. Finally, TD Securities reissued a “hold” rating and set a C$18.50 target price on shares of Valeant Pharmaceuticals Intl in a research report on Friday, February 17th.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply